Skip to main content

Complement Therapeutics Appoints Dominic Moreland as Chief Financial Officer 

Munich, Germany – 27th April 2023 – Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the appointment of Dominic Moreland as its Chief Financial Officer. Dominic brings with him extensive experience in finance and operations, having held senior leadership roles in several biotech companies previously.  

Dominic is a seasoned biopharmaceutical executive with many years experience in the sector and previously served as the finance lead at Autolus Therapeutics through the company’s IPO and NASDAQ listing. He led the MBO and subsequent trade sale of a division of Genzyme Therapeutics UK and prior to that held finance positions with Baxter Healthcare and Zeneca. Dominic is a Chartered Accountant and holds a B.Sc from the London School of Economics. 

“We are thrilled to welcome Dominic to the Complement team as CFO,” said Rafiq Hasan, Chief Executive Officer. “Dominic’s experience in financial management will be invaluable as we continue to grow the organisation and develop our pipeline. He played a critical role in the recent successful Series A funding round and we are excited to have him on board to help transform the treatment landscape for complement-mediated diseases.”  

“Joining Complement Therapeutics at this stage in the company’s development is a truly exciting opportunity. I believe the team has the potential to make a real difference in the lives of patients with complement-mediate diseases, and I am delighted to be part of it. I look forward to working with the great team we have assembled and building a strong financial foundation for the company as we progress to the clinic.” said Dominic Moreland. 

About Complement Therapeutics GmbH: 

Complement Therapeutics GmbH (CTx) is a German headquartered early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade.  

Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for GA, a leading cause of blindness. Additional programs will evaluate potential therapeutic opportunities in other complement-mediated conditions.  

The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable the quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease. 

The Company has subsidiaries in the UK (Complement Therapeutics Ltd) and in the USA (Complement Therapeutics Inc) as well as research laboratories in Stevenage, UK. 


For more information please visit: 

Company Contact 

Dr Rafiq Hasan, CEO and Managing Director 

Complement Therapeutics GmbH